Special Issue

Killing It Softly–New Approaches to Overcome Cancer Chemoresistance

Message from the Guest Editors

Oncological therapy is an unequal fight with a dangerous opponent. In response to chemotherapeutic drugs or radiotherapy, cancer cells activate several molecular mechanisms that ensure survival and further cancer progression. Examples of mechanisms determining chemo- and radio-resistance include the constitutive activity of survival factors, namely: NF-kB, pSTAT3, expression of MDR multidrug resistance proteins, glycolytic phenotype, shedding of TNF family death-ligand receptors, and many others. Because of the wealth of protective mechanisms, the available chemotherapeutic agents do not meet the need for effective cancer elimination. Therefore, there is an urgent need for the continuous improvement of anti-cancer therapy to reduce the phenomenon of chemoresistance and to effectively attack cancer cells. In the development of medicine, biotechnology, nanomedicine, and molecular biology techniques, anti-cancer therapy progress is also significant.

We cordially invite authors in the field to submit original research or review articles pertaining to this field of biomedicine.

Guest Editors

Prof. Dr. Beata Pajak-Tarnacka

Biological and Chemical Research Center, University of Warsaw, Zwirki i Wigury 101, 02-089 Warsaw, Poland

Dr. Anna Jaśkiewicz

Independent Laboratory of Genetics and Molecular Biology, Kaczkowski Military Institute of Hygiene and Epidemiology, Kozielska 4, 01-183 Warsaw, Poland

Deadline for manuscript submissions

closed (30 September 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/73357

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).